Rezultati - Luong V. Hoang

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial od Thuy P. Nguyen, Quyet Do, Lan T. Phan, Duc V. Dinh, Hiep Khong, Luong V. Hoang, Thuong V. Nguyen, Hung N. Pham, Men V. Chu, Toan T. Nguyen, Quang D. Pham, Tri M. Le, Tuyen N.T. Trang, Thanh T. Dinh, Thuong V. Vo, Thao T. Vu, Quynh B.P. Nguyen, Vuong T. Phan, Luong V. Nguyen, Giang T. Nguyen, Phong M. Tran, Thuan D. Nghiem, Tien V. Tran, Tien G. Nguyen, Tuynh Q. Tran, Linh T. Nguyen, Anh T. Do, Dung D. Nguyen, Son A. Ho, Viet T. Nguyen, Dung T. Pham, Hieu B. Tran, Son T. Vu, Su X. Hoang, Trung M. Do, Xuan T. Nguyen, Giang Q. Le, Ton Tran, Thang M. Cao, Huy M. Dao, Thao T.T. Nguyen, Uyen Y Doan, Vy T.T. Le, Linh P. Tran, Ngoc M. Nguyen, Ngoc T. Nguyen, Hang T.T. Pham, Quan H. Nguyen, Hieu T. Nguyen, Hang L.K. Nguyen, Vinh T. Tran, Mai T.N. Tran, Truc T.T. Nguyen, Phat T. Ha, Hieu T. Huynh, Khanh D. Nguyen, Ung T. Thuan, Chung C. Doan, Si M. Do

Connect to this object online.